Drug Profile
Research programme: protein kinase inhibitors - Oncodesign
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Oncodesign Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Receptor-interacting protein serine-threonine kinase 2 inhibitors; Salt-inducible kinase-2 inhibitors; Transforming growth factor beta type II receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis; Crohn's disease; Glioblastoma; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Crohn's-disease in France
- 30 Oct 2019 Early research in Crohn's-disease is ongoing in France
- 28 Aug 2018 No recent reports of development identified for research development in Arthritis in France